The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older
Key facts
- Who runs it
- Seqirus
- Where
- Baton Rouge, Binghamton, Chicago, Cincinnati, Clearwater, Cleveland, Columbia, Dallas, Doral, East Greenwich, East Syracuse, Edgewater, Fort Worth, Gaffney, Gulfport, Gurnee, Houston, Huntington Beach, Jupiter, Kansas City, Knoxville, Largo, Las Vegas, Little Rock, Medford, Meridian, Metairie, Miami Lakes, Milford, Monroe, Nashville, New York, Norfolk, Omaha, Plano, Raleigh, Redding, Rockville, Salt Lake City, Sioux City, Spartanburg, St Louis, Suffolk, Sunrise, Tampa, Tempe, Tomball, Valparaiso, Waterbury, and West Jordan, United StatesSee the 51 sitesAlso in 7 other countries, 45 sites
- Trial code
- Status
- Completed
- Phase
- Phase 3
- People taking part
- 7,741 people enrolled
- Started
- 3 Nov 2023
- Ended
- 30 Jan 2025
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Investigational aQIVc
- licensed QIVr
- licensed aQIV
- Record updated
- 27 April 2025
Who can take part
- Age
- 50 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 9 criteriaShow less
Other criteria
- Main Inclusion Criteria:
- Individuals, aged 50 years and older, who are healthy or have stable comorbidities that increase their risk of complications from influenza infection
- Individuals who can comply with all study procedures; Main Exclusion Criteria:
- Progressive, unstable, or uncontrolled clinical conditions
- Known hypersensitivity or allergy to any study vaccine component
- Known history of Guillain-Barré syndrome or other demyelinating disease
- Condition representing a contraindication to vaccination or blood draw
- Abnormal function of immune system due to known disorder or medication
- Influenza vaccination within 180 days prior to informed consent
Where in United States
Also in 7 other countries, 45 sites
- Velocity Clinical Research, Baton RoughBaton Rouge, United States
- Velocity Clinical Research - BinghamtonBinghamton, United States
- Great Lakes Clinical Trials, LLC Ravenswood dba Flourish ResearchChicago, United States
- CTI Clinical Research CenterCincinnati, United States
- Velocity Clinical Research - CincinnatiCincinnati, United States
- Innovative Research of West Florida, Inc.Clearwater, United States
- Velocity Clinical Research, ClevelandCleveland, United States
- Centennial Medical Group, PCColumbia, United States
- Cedar Health Research, LLCDallas, United States
- USA and International Research Inc.Doral, United States
- Velocity Clinical Research, ProvidenceEast Greenwich, United States
- Velocity Clinical Research, SyracuseEast Syracuse, United States
- Velocity Clinical Research New Smyrna BeachEdgewater, United States
- Benchmark ResearchFort Worth, United States
- Velocity Clinical Research, GaffneyGaffney, United States
- Velocity Clinical Research, GulfportGulfport, United States
- Great Lakes Clinical Trials, LLC. Ravenswood dba Flourish ResearchGurnee, United States
- DM Clinical Research - Martin Diagnostic ClinicHouston, United States
- Marvel Clinical ResearchHuntington Beach, United States
- Health Awareness, IncJupiter, United States
- Alliance for Multispecialty Research, LLCKansas City, United States
- AMR KnoxvilleKnoxville, United States
- ARS - Lake OconeeLargo, United States
- Alliance for Multispecialty Research (AMR) LLC, Las VegasLas Vegas, United States
- Baptist Health Center for Clinical ResearchLittle Rock, United States
- Velocity Clinical Research, MedfordMedford, United States
- Velocity Clinical Research, BoiseMeridian, United States
- Benchmark ResearchMetairie, United States
- Global Health Research CenterMiami Lakes, United States
- Clinical Research Consulting, Inc.Milford, United States
- IMA Evaluations LLCMonroe, United States
- Clinical Research Associates, Inc.Nashville, United States
- Velocity Clinical Research, VestalNew York, United States
- Velocity Clinical Research - NorfolkNorfolk, United States
- Velocity Clinical Research - OmahaOmaha, United States
- ACRC trials Parent HQPlano, United States
- M3 Wake Research, Inc.Raleigh, United States
- Paradigm Clinical Research Center, LLCRedding, United States
- Velocity Clinical Research, RockvilleRockville, United States
- BBCR Holdings LLC dba JBR Clinical Research - Midvale CampusSalt Lake City, United States
- Velocity Clinical Research - Sioux CitySioux City, United States
- Velocity Clinical Research, SpartanburgSpartanburg, United States
- Sundance Clinical ResearchSt Louis, United States
- Velocity Clinical Research, SuffolkSuffolk, United States
- Precision Clinical ResearchSunrise, United States
- Global Health Research centerTampa, United States
- Alliance for Multispecialty Research (AMR) PhoenixTempe, United States
- DM Clinical ResearchTomball, United States
- Velocity Clinical Research ValparaosoValparaiso, United States
- Chase Medical Research, LLCWaterbury, United States
- Velocity Clinical Research, Salt Lake CityWest Jordan, United States
About the trial
What the trial wants to find out
This is a Phase 3, randomized, parallel-group, comparator-controlled, observer-blind, multicenter study of immunogenicity and safety in approximately 7700 male and female adults aged 50 years and older (approximately equally split between two age groups: 50-64 years; 65 years and older), who are healthy or have stable comorbidities that increase their risk of complications from influenza infection. Three lots of aQIVc will be evaluated for consistency and pooled for the comparison with the 2 control vaccines.
Read full original descriptionShow less
Subjects will be randomly assigned to receive 1 of 3 lots of aQIVc, QIVr, or aQIV in a 1:1:1:2:2 ratio (for a 3:2:2 ratio for aQIVc, QIVr, and aQIV).
The study will have a treatment period (Day 1 to Day 29) and a follow-up period (Day 30 up to Day 181); a subset of 770 subjects will be followed up up to Day 365.
The 3 groups in the trial
- Investigational aQIVc groupTreatment being tested
Treatment: Investigational aQIVc
- licensed QIVr groupExisting treatment, for comparison
Treatment: licensed QIVr
- licensed aQIV groupExisting treatment, for comparison
Treatment: licensed aQIV
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 3, Randomized, Observer-Blind, Controlled, Multicenter, Clinical Study to Evaluate Immunogenicity and Safety of a MF59-Adjuvanted Quadrivalent Subunit Cell-derived Influenza Vaccine (aQIVc) in Comparison With Quadrivalent Influenza Vaccines, in Adults Aged 50 Years and Older.
- Publications
- Immunogenicity and safety of an MF59-adjuvanted cell-derived higher-dose quadrivalent influenza vaccine (aQIVc) in adults aged 50 years or older: a phase 3 randomised controlled trial.The Lancet. Infectious diseases, 2026
- Immunogenicity and safety of higher-dose cell-based adjuvanted quadrivalent influenza vaccines: Combined results of randomised, controlled dose-finding and dose-confirmation studies.Vaccine, 2026
- Record updated
- 27 April 2025